Early granulocyte colony stimulating factor administration increases the risk of cytokine release syndrome in acute lymphoblastic leukemia patients receiving anti-CD19 chimeric antigen receptor T-cell therapy.
Sign Up to like & getrecommendations! Published in 2023 at "Hematological oncology"
DOI: 10.1002/hon.3188
Abstract: Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and neutropenia are common toxicities associated with chimeric antigen receptor T (CAR-T) cell therapy. The role of granulocyte colony stimulating factor (G-CSF) in CAR-T-cell-treated patients… read more here.
Keywords: cell; administration; group; patients receiving ... See more keywords